Loading patent…
AssigneeCentral Iowa Health System
InventorsCharles J. LINK, JR., Tatiana Seregina, Gabriela Rossi
Estimating the term…
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
1-39. (canceled)
A pharmaceutical composition comprising a tumor cell preparation obtained from a human tumor cell line, each cell comprising a plurality of cell surface glycoproteins on which an αGal epitope is present, wherein αGal epitopes are present in an amount effective to treat a pre-existing tumor, suspended in a pharmaceutically acceptable carrier suitable for injection in human patients.
A method of making a master cell bank of whole cell vaccines for the treatment of cancer comprising:
Dependencies are inferred from the claim text.